AAIC 2025 Abstract
Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations
Trial in peopleInterventions
Abstract
Background: A subcutaneous formulation of the anti‐amyloid antibody lecanemab is being developed to improve patient convenience and safety.
